RASP.US Rasna Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0005 USD
Close of Oct 5, 2026
0.0005 0.0040
Market cap
USD 386K
P/E
-
P/B
0.31x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Mar 2024.

Is RASP.US undervalued?

Graham number

The Graham number of Rasna Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rasna Therapeutics Inc fundamental analysis

No fundamental analysis for Rasna Therapeutics Inc yet.

Rasna Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rasna Therapeutics Inc

Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301. The company was formerly known as Rasna Therapeutics, Inc. and…

Full company profile